2015
DOI: 10.1007/s00277-015-2316-0
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death

Abstract: Nowadays in many fields of medicine, prognostic scores are used to predict the outcome for individual patients. In chronic myeloid leukemia (CML), the Sokal, the Euro, and the EUTOS score are established prognostic scores which were addressed by the CML management recommendations of the European LeukemiaNet. This review provides a general definition of prognostic scores and explains their meaning. Main differences between the Sokal, the Euro, and the EUTOS score are highlighted. Due to the therapeutic success … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
24
0
2

Year Published

2015
2015
2021
2021

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 27 publications
(27 citation statements)
references
References 34 publications
1
24
0
2
Order By: Relevance
“…We employed the cumulative incidence procedure and the Fine-Gray test to estimate and compare the probabilities of IFFS, PFS, and CML OS for the high and low gene expression groups [41]. Non-CML-related deaths and changes from imatinib due to toxicity were considered competing risks in the analysis of IFFS.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…We employed the cumulative incidence procedure and the Fine-Gray test to estimate and compare the probabilities of IFFS, PFS, and CML OS for the high and low gene expression groups [41]. Non-CML-related deaths and changes from imatinib due to toxicity were considered competing risks in the analysis of IFFS.…”
Section: Methodsmentioning
confidence: 99%
“…In order to evaluate a prognostic test, it is important to test its performance in a cohort as similar as possible to the real scenario [28]. In addition, because CML is a chronic disease, competing risk has been accepted as a better option for analysis [29]. Finally, employing more control genes may produce a more consistent result, but that strategy is quite time-consuming, which restricts its applicability [30].…”
Section: Introductionmentioning
confidence: 99%
“…Clearly, these attempts were successful or not depending statistical methods used (mostly Cox multivariate analysis and more recently causespecific or sub distribution hazard models) and the numbers of patients included into retrospective studies designed for prognostic score estimation. Importantly, in addition to that these groups of patients had to be treated with homogenous treatment able to achieve similar results [1]. The result of this approach is usually the number which value allocates the individual patient to the specific prognostic group ("low", "intermediate" or "high" risk).…”
Section: Commentarymentioning
confidence: 99%
“…Various strategies were proposed: 1/ to use different endpoints because more CML patients treated successfully with TKI are dying from different causes than CML. Logically the German group of statisticians analyzed with this aim 1236 patients treated within the German CML Study IV and find out that the best model for prediction of CML-related deaths may be based on age, gender and spleen size [1]; 2/ to combine existing scoring systems with the results of early molecular response (proved to correlate with further response and survival in may trials) [14]; 3/ combination the various existing scores within a new one. The group of Korean scientists recently confirmed different probabilities of achieving complete cytogenetic response at 12 month for the groups of patients with combination of low scores and for the patients who have all three scores (Sokal, Euro and EUTOS) in the high-risk group categories [15]; 4/ to use novel biological or molecular markers that may further improve the prognostication [16,17].…”
Section: Commentarymentioning
confidence: 99%
“…5,6 The long-term cumulative probability of progression of CML from CP to BP is only about 5%. 7,8 Despite the revolutionary progress in the treatment of patients with CML-CP, CML-BP remains a therapeutic challenge. In general, CML-BP is a fatal disease in the era of TKI therapy, with a median survival of only 6–10 months.…”
mentioning
confidence: 99%